News & Insights

In 2026, buyers and lenders are no longer just underwriting a food manufacturer’s past performance. They are underwriting how hard the next chapter looks. That shift – driven by converging capital constraints, an aggressive federal health agenda, and regulatory uncertainty unlike anything the sector has seen in decades – is creating a widening gap between businesses that are ready and those that still have work to do.

Most of the pressures facing privately held food manufacturers in 2026 are not new. Labor costs, input volatility, food safety requirements, customer concentration, and regulatory scrutiny have been part of the sector for years. What is new is the timing: operators are now being required to fund operational, compliance, and supply-chain change at exactly the moment when capital is less available, more expensive, and more scrutinizing of execution risk.

That collision – required investment meeting a tighter capital environment – is what makes 2026 structurally different. The businesses most likely to emerge stronger will not be the ones with the most ambitious growth story. They will be the ones that can demonstrate control over margins, compliance, supplier relationships, and the timing of their next move before external parties start asking the questions.

This is the readiness premium. And in the current market, it is real.

The Setup: Required Investment Meets a Tighter Capital Market

For middle-market food manufacturers, the sequence of decisions has changed. A few years ago, it was reasonable to address operational, regulatory, and strategic issues in order – automation first, then compliance, then financing. Today, those decisions have to be made in parallel, and each one affects the others.

The lending environment reflects this directly. Three years ago, a food manufacturer could finance an acquisition or major capex project with debt equal to roughly 4.7 times EBITDA – and borrow that money at an all-in cost of around 6%. Today, lenders are generally sizing debt at around 4.1x EBITDA, and the all-in borrowing cost sits closer to 8.5%. That may sound like a modest shift, but on a $10 million project it means less of the investment gets financed with debt, the annual interest burden is meaningfully higher, and the loan almost certainly comes with tighter covenant tests than it would have in 2021. For a middle-market food manufacturer already managing margin pressure and a compliance agenda, that change in the financing math is not a background condition – it is a direct constraint on what investments are feasible and when.

The result is a compounding challenge. Higher borrowing costs increase the price of the very capex that regulatory and competitive pressures are making necessary. Tighter lending standards reduce flexibility when execution slips. And for founder-led or sponsor-backed middle-market businesses – unlike larger strategics who can absorb dislocation across a broader platform – execution risk is not abstract. A sensible investment arriving at the wrong time on the balance sheet can create real problems.

The question is no longer whether to invest. It is whether the business can absorb the investment without creating problems in financing, diligence, or exit timing.

One specific friction point worth flagging early: manufacturers sourcing perishable agricultural commodities operate under PACA, which creates a statutory trust giving unpaid produce suppliers priority claims over inventory, receivables, and proceeds – ahead of secured lenders in insolvency scenarios. In a permissive credit environment, lenders often worked around that complexity. Today they are less willing to. Businesses with mixed sourcing profiles, inconsistent payment practices, or weak trust preservation documentation are more likely to encounter tighter diligence and a more conservative collateral assessment. PACA compliance is a financing matter, not just a legal one – and in 2026, it belongs in the same conversation as capex planning and covenant management.

Tariffs: A Cost Wave That Hasn’t Fully Hit Yet

For manufacturers sourcing ingredients internationally, tariffs are becoming a real margin issue – and the worst of it is still ahead. A 10% baseline tariff now applies to most imports, with higher rates on top for goods from Canada, Mexico, and China – the three largest food ingredient sources for U.S. manufacturers. For categories like packaged foods and snacks, landed input costs on ingredients like palm oil, cocoa, and processed sugar have risen by up to 25%. Packaging materials – aluminum foil, flexible film, certain paper substrates – carry heavy Chinese-origin exposure and are seeing similar increases.

What makes this particularly relevant for owners thinking about a financing or sale process is timing. Manufacturers have largely absorbed these costs rather than passing them to consumers, but that cushion is running out. Analysts expect 2026 to be the year tariff costs start flowing through to retail prices – meaning a buyer or lender underwriting a business today will want to understand ingredient sourcing geography, tariff exposure by category, and what flexibility exists to manage it. That is now a diligence question, not just an operations one.

MAHA: The Regulatory Wildcard Reshaping Product Strategy

The most disruptive new force in food manufacturing regulation is not coming from traditional food safety channels. It is coming from the Make America Healthy Again (MAHA) movement – and it is moving faster, and with less predictability, than anything the sector has seen in a generation. The core challenge is structural: MAHA-driven policy is advancing through a mix of formal rulemaking, voluntary industry agreements, executive directives, and state-level legislation – simultaneously and often inconsistently.

Synthetic Dyes:

FDA and HHS announced the phase-out of eight petroleum-based synthetic dyes by end of 2026. FD&C Red No. 3 authorization revoked effective January 2027. Industry analysts estimate ~23% of all new U.S. food and beverage launches in 2025 contained a MAHA-targeted ingredient; ~40% of major manufacturer products versus 18% of independent brands.

Critically, much of this policy is not yet law. It is advancing through speeches, voluntary agreements, and informal directives – meaning there is no assurance that a future administration won’t reverse course. For manufacturers, that ambiguity is itself the problem: the cost of reformulating is real and immediate, but the regulatory floor is uncertain.

GRAS:

The FDA is considering changes that could eliminate the GRAS self-affirmation pathway, which has historically allowed manufacturers to introduce certain ingredients without premarket FDA review. A proposed rule is expected. At the same time, New York, New Jersey, and Pennsylvania have pending legislation that would require state notification of self-affirmed GRAS substances. The FDA is also moving toward a federal definition of ultra-processed foods (UPFs), which could have downstream implications for SNAP and school lunch eligibility, as well as buyer diligence and underwriting of food product portfolios.

State-Level Patchwork:

West Virginia has banned several artificial dyes and preservatives effective 2028. Texas now requires warning labels on products with any of 44 listed ingredients. California and New York advancing additional restrictions.

MAHA is not a passing political moment. Even if specific rules are reversed or delayed, the consumer demand it is amplifying – for cleaner labels, simpler ingredient decks, and greater transparency – is durable.

Labor: The Persistent Cost the Balance Sheet Has to Absorb

In 2026, automation is no longer just an operational decision – it is a financing one. The investment introduces transitional risk before it delivers savings: ramp-up disruption, covenant headroom pressure, and near-term liquidity demands that arrive before the cost reduction does. In a permissive credit environment, lenders could work around that gap. Today, they are less willing to. Companies that can frame automation as a structured risk reduction – with a clear payback timeline, credible implementation plan, and capital structure that accommodates the transition – are in a materially better position than those presenting it as a future aspiration.

The underlying driver is straightforward. Food manufacturing remains one of the most labor-intensive industries in the U.S. economy. The Bureau of Labor Statistics reports roughly 1.78 million employees in the sector, with production workers averaging $24.43 per hour and average weekly hours at 40.5. That cost structure is not going away – and it is precisely why automation investment remains strategically important despite its upfront capital demands. Labor is not just an operating cost. It is a source of earnings volatility that lenders underwrite and buyers’ discount.

Exhibit 1: U.S. Food Manufacturing Labor Snapshot

A company evaluating a new automated packaging line or a throughput improvement project is therefore asking two questions simultaneously: whether the project improves efficiency, and whether the business can absorb ramp-up risk, preserve covenant headroom, and maintain lender confidence while the project is being implemented. In 2026, the second question is often the harder one.

Exhibit 2: Key Cost Pressures Facing Food Manufacturers

Traditional Regulatory Change: Still a Financing and Diligence Issue

Alongside MAHA, FDA’s 2026 Human Foods Program priorities include a continued push on allergen transparency, front-of-package nutrition labeling, natural color alternatives, and updated standards around the ‘healthy’ nutrient content claim finalized in late 2024. These are not new conversations, but the pace of implementation is accelerating.

The key implication is that non-compliance – or even the appearance of deferred compliance – is increasingly surfacing in buyer diligence and lender underwriting. A company with open formulation issues, inconsistent labeling, or unresolved ingredient questions is carrying valuation risk, not just regulatory risk.

The same logic applies to traceability. FDA proposed extending the Food Traceability Rule compliance date to July 20, 2028, and Congress directed the agency not to enforce the rule before that date. Better-prepared businesses are using the window to build traceability infrastructure proactively – turning an eventual compliance requirement into a current commercial capability.

Compliance deferred is not compliance avoided. In today’s market, open regulatory issues are increasingly priced into valuation – before a process even begins.

Traceability Is Becoming a Commercial Capability, Not Just a Compliance Requirement

Consumer expectations around food safety and transparency have hardened. A 2025 GS1 US survey found that 93% of Americans are concerned about the frequency of food recalls, 60% have avoided an entire food category following a recall, and 59% remained hesitant to repurchase from the same brand afterward.

Traceability – lot-level visibility, supplier documentation, rapid response capability – is increasingly part of what major retailers, large food service customers, and acquirers expect to see before committing to a relationship or a transaction. The businesses that have invested ahead of the mandate are not just more compliant. They are more defensible in diligence, more credible in retailer conversations, and better positioned to protect brand equity when issues arise.

Where the Pressure Is Most Acute by Subsector

The challenge is not uniform across food manufacturing. Different subsectors are experiencing the same capital-and-execution squeeze through different bottlenecks.

Protein and cold chain businesses remain exposed to labor intensity, logistics complexity, refrigeration infrastructure needs, and volatile input economics. For them, the pressure often shows up in operating stability and capital intensity at the same time.

Industrial baking and private label businesses often face retailer-driven pricing pressure, limited room for error on margin, and growing need to adjust formulations or ingredients without disrupting service or customer relationships. The operating model leaves less room to absorb missteps.

Ingredients and specialty products may be better positioned where they benefit from cleaner-label demand, functional formulations, or reformulation support. The strategic opportunity can be stronger here, but buyers still tend to distinguish sharply between businesses with scalable differentiation and those with less-defensible exposure.

Snacks and packaged food businesses face a more acute version of the MAHA problem. With a disproportionate share of product portfolios containing targeted dyes and ingredients, these businesses are navigating simultaneous pressure to reformulate, manage SKU complexity across a patchwork of state requirements, and absorb the cost and timeline risk of reformulation – often without meaningful margin buffer to absorb the disruption.

The right question for an owner is not ‘how is food manufacturing doing?’ It is: ‘which pressure point matters most in my category, and what does that mean for financing, timing, and readiness?

Valuation in 2026: The Premium Is Increasingly for Preparedness

Valuation in today’s market is not just a function of scale, EBITDA, or category attractiveness. The numbers tell a bifurcated story. Average sector M&A EBITDA multiples for food have reached 14.7x in the 2023–2025 period, more than three EBITDA multiple points above than the 11.5x average from 2020–2022 – but that headline figure is heavily skewed by better-for-you and clean-label transactions where strategics are paying premiums for growth and reformulation-readiness. For middle-market food manufacturers in conventional categories, the reality is more like 6x to 9x EBITDA depending on category, margin quality, and diligence outcomes, with top-quartile businesses achieving the upper end and everything else clearing at a discount or requiring deal structure to close. The median EV/EBITDA multiple for PE deals in the Food & Consumer sector increased to 10.8x in 2025 from 6.7x in 2024, while strategic buyers moved in the opposite direction – declining to 8.5x from 14.7x – a divergence that reflects PE’s renewed appetite for platform building against strategics’ growing selectivity about what fits their portfolios.

That split between strategic and financial buyers’ matters for owners thinking about exit options. Strategics are currently reshaping portfolios – pruning non-core assets and acquiring targeted capabilities – which means they are highly selective and paying premiums only when the acquisition directly accelerates a specific thesis (cleaner labels, functional ingredients, supply chain control). PE platforms are more focused on roll-up logic, bolt-on fit, and add-on pipeline, and prize operational levers like SKU rationalization and co-manufacturing transition plans. Both buyer types are doing more structural work to close – earnouts, seller notes, and tighter working capital mechanics are now standard in ways they were not in 2021–2022. A business that enters a process with unresolved MAHA exposure, open capex needs, or weak traceability documentation is handing either buyer type a reason to reprice.

For food manufacturers, that means the spread between average and premium outcomes is increasingly driven by perceived forward risk. Businesses that can demonstrate cleaner records, better visibility into margins and customer concentration, stronger supplier discipline, and fewer near-term operational or regulatory uncertainties are better positioned to support premium outcomes. Businesses with active MAHA ingredient exposure, unresolved formulation plans, or open traceability gaps are increasingly facing harder diligence conversations and more valuation pressure.

Buyers are not underwriting historical performance alone. They are underwriting how hard the next chapter looks. In 2026, that next chapter includes an ingredient regulatory environment unlike any the sector has previously navigated.

To illustrate how these dynamics interact in practice: consider a mid-size private-label snack manufacturer – around $40M in revenue, solid EBITDA margins, a clean balance sheet, and a management team that had been thinking about a sale within two years. Eighteen months before approaching the market, the business began a proactive review: mapped its MAHA ingredient exposure across the SKU portfolio, identified three formulations that would require reformulation ahead of any buyer process, built out lot-level traceability documentation, and addressed a working capital cycle that had been creating financing friction. When it ran a process, it cleared 8.5x EBITDA with two strategic bidders and a PE platform competing. A comparable business in the same category – similar size, similar margins, but with open reformulation questions and a thinner compliance file – transacted at 6.2x the same quarter, with an earnout attached to post-close formulation milestones. The gap between those outcomes was not category or EBITDA. It was readiness.

What Owners Should Assess Now

For many food manufacturers, strategy in 2026 is becoming less about optimizing a single variable and more about balancing multiple forms of risk at once: margin pressure, compliance burden, supply continuity, and financing flexibility.

That makes the immediate agenda more specific than a generic call for discipline. Owners should be asking:

1. Does our current capital structure still fit the investments we know we need to make?
2. What is our MAHA ingredient exposure across the SKU portfolio, and do we have a credible, documented reformulation plan that a buyer or lender could evaluate?
3. Are there regulatory, formulation, labeling, or traceability gaps that could become diligence issues?
4. Are there supplier, working-capital, or PACA-related exposures that would matter more in a financing conversation today than they would have several years ago?
5. If we were in front of a buyer in six to twelve months, what part of the story would still feel unfinished?

These questions matter because in this market, “not yet ready” can be more expensive than “not yet for sale.”

Final Thoughts

The pressures described in this article are interconnected in ways that are easy to underestimate. A capex decision that seems operationally sound can create covenant pressure at exactly the wrong moment. A MAHA-related reformulation initiative that seems manageable internally can reframe a buyer’s view of forward risk if the timeline is unclear or the cost is unfunded. An ingredient issue that feels like background regulatory noise today can become the center of a valuation conversation in twelve months. These interactions, not any single pressure in isolation, are what make 2026 genuinely different to navigate.

What remains less well understood is not the existence of these pressures, but the way they compound. Issues that appear manageable on a standalone basis can become more consequential when they begin to affect financing flexibility, diligence narratives, and buyer confidence at the same time. That is where Harney Capital’s perspective is distinct. The focus is not simply on identifying familiar industry risks, but on understanding how unfunded capex needs, MAHA ingredient exposure, PACA-related constraints, formulation challenges, traceability gaps, and capital structure mismatches can converge in ways that alter timing, process structure, and ultimately outcome. That is also where Harney Capital believes thoughtful preparation can meaningfully influence not just execution, but the quality of the outcome itself.

The businesses that will create stronger outcomes in this environment are not necessarily the ones with the best categories or the strongest trailing EBITDA. They will be the ones that saw the convergence coming, capital constraints, MAHA uncertainty, and tighter lender scrutiny, and treated preparation as a strategic act rather than a precondition for getting a deal done.

That distinction matters because the window is not permanent. The operators who address their MAHA exposure, clean up their capital structure, and build traceability infrastructure now are not just reducing risk. They are widening the gap between themselves and the businesses still waiting to get organized. In twelve to eighteen months, that gap will show up in valuation, in process outcomes, and in which businesses have options and which ones are reacting to circumstances they can no longer control.

The readiness premium is available to anyone willing to pursue it before they need it. That is the whole point.

Sources Referenced

• Federal Reserve – March 18, 2026 FOMC statement
• Federal Reserve – January 2026 Senior Loan Officer Opinion Survey
• USDA Economic Research Service – Food Price Outlook, March 2026
• U.S. Bureau of Labor Statistics – Food Manufacturing (NAICS 311)
• FDA – Human Foods Program 2026 Priority Deliverables
• FDA – FSMA Food Traceability Rule guidance and proposed compliance extension
• GS1 US – 2025 Food Safety Recall Survey
• USDA AMS – PACA common questions
• PwC – 2026 consumer markets M&A outlook
• Baker Tilly – Food and beverage M&A update
• HHS/FDA – Synthetic Dye Phase-Out Announcement (April 2025)
• Wiley Law – Food Industry Braces for MAHA and Other Challenges in 2026 (January 2026)
• Holland & Knight – FDA: What to Watch in 2026 and Beyond
• Food Navigator-USA – MAHA Push Accelerates Reformulation (April 2026)
• Innova Market Insights – MAHA Ingredient Exposure Data (2025)
• GF Data – M&A Report Q1 2025
• Capstone Partners – Middle Market Leveraged Finance Update Q4 2025
• Capstone Partners – Food Mergers & Acquisitions Update, November 2025
• RL Hulett – Food & Consumer M&A Update Q4 2025
• Auxo Capital Advisors – Food & Beverage Valuation Multiples 2026
• Webgility – Current Trends in Food and Beverage Industry (tariff landscape)
• Dairy Reporter – Tariffs Haven’t Fully Hit Food Yet, January 2026